MARC details
000 -LEADER |
fixed length control field |
02724nam a22003377a 4500 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
180220s20182018 xxu||||| |||| 00| 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
International Standard Serial Number |
2213-1779 |
024 ## - OTHER STANDARD IDENTIFIER |
Standard number or code |
10.1016/j.jchf.2017.08.024 [doi] |
024 ## - OTHER STANDARD IDENTIFIER |
Standard number or code |
S2213-1779(17)30622-4 [pii] |
040 ## - CATALOGING SOURCE |
Original cataloging agency |
Ovid MEDLINE(R) |
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
PMID |
29413379 |
245 ## - TITLE STATEMENT |
Title |
Left Ventricular Dysfunction in Cancer Treatment: Is it Relevant?. [Review] |
251 ## - Source |
Source |
JACC Heart Failure. 6(2):87-95, 2018 Feb |
252 ## - Abbreviated Source |
Abbreviated source |
JACC Heart Fail. 6(2):87-95, 2018 Feb |
253 ## - Journal Name |
Journal name |
JACC. Heart failure |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Year |
2018 |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Manufacturer |
FY2018 |
266 ## - Date added to catalog |
Date added to catalog |
2018-02-20 |
520 ## - SUMMARY, ETC. |
Abstract |
Contemporary cancer therapies have dramatically improved cancer-free and overall survival but have been accompanied by increasing cancer treatment-related cardiovascular toxicity, including left ventricular (LV) systolic dysfunction. Previously, systemic chemotherapy with anthracyclines and radiation therapy were the only cancer treatments with significant cardiotoxicity. However, modern targeted cancer therapies, including HER2 inhibitors, tyrosine kinase inhibitors (TKIs), proteasome inhibitors, and immune checkpoint inhibitors, have all been associated with adverse cardiovascular events. As cancer treatment paradigms successfully move toward prolonged targeted therapy, cardiologists are increasingly needed to assess cardiotoxicity risk and manage asymptomatic and symptomatic LV systolic dysfunction. This state of the art review summarizes the present knowledge about the mechanisms and clinical practices of screening, diagnosis, and management of LV dysfunction associated with cancer therapeutic regimens. We utilize the framework of the ACCF/AHA stages of heart failure (HF) to summarize current evidence for risk stratification and modification (Stage A HF), asymptomatic structural heart disease detection and treatment (Stage B HF), and reduction of HF morbidity and mortality (Stages C and D HF) during cancer treatment and in survivorship. We also present new clinical practice challenges and opportunities for active engagement of cardiologists with multidisciplinary cancer treatment teams in order to ensure optimal patient outcomes. |
520 ## - SUMMARY, ETC. |
Abstract |
Copyright (c) 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. |
546 ## - LANGUAGE NOTE |
Language note |
English |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
IN PROCESS -- NOT YET INDEXED |
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
Institution |
MedStar Heart & Vascular Institute |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Journal Article |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Review |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Barac, Ana |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Kenigsberg, Benjamin |
790 ## - Authors |
All authors |
Barac A, Kenigsberg B, Wellstein A |
856 ## - ELECTRONIC LOCATION AND ACCESS |
DOI |
<a href="https://dx.doi.org/10.1016/j.jchf.2017.08.024">https://dx.doi.org/10.1016/j.jchf.2017.08.024</a> |
Public note |
https://dx.doi.org/10.1016/j.jchf.2017.08.024 |
942 ## - ADDED ENTRY ELEMENTS (KOHA) |
Koha item type |
Journal Article |
Item type description |
Article |